AVTE
Income statement / Annual
Last year (2023), Aerovate Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Aerovate Therapeutics, Inc.'s net income was -$75.52 M.
See Aerovate Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$96,000.00 |
$68,000.00 |
$15,000.00 |
$1,000.00 |
$0.00 |
| Gross Profit |
-$96,000.00 |
-$68,000.00 |
-$15,000.00 |
-$1,000.00 |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$64.22 M
|
$38.62 M
|
$14.99 M
|
$7.94 M
|
$3.11 M
|
| General & Administrative
Expenses |
$17.19 M
|
$14.62 M
|
$8.04 M
|
$949,000.00
|
$218,000.00
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$17.19 M
|
$14.62 M
|
$8.04 M
|
$949,000.00
|
$218,000.00
|
| Other Expenses |
$0.00 |
-$79,000.00 |
-$3,000.00 |
-$647,000.00 |
$1,000.00 |
| Operating Expenses |
$81.41 M |
$53.24 M |
$23.02 M |
$8.89 M |
$3.33 M |
| Cost And Expenses |
$81.41 M |
$53.24 M |
$23.02 M |
$8.89 M |
$3.33 M |
| Interest Income |
$5.95 M |
$1.83 M |
$65,000.00 |
$75.00 |
$0.00 |
| Interest Expense |
$0.00 |
$0.00 |
$65,000.00 |
$75,000.00 |
$0.00 |
| Depreciation &
Amortization |
$96,000.00
|
$68,000.00
|
$15,000.00
|
$1,000.00
|
$3.33 M
|
| EBITDA |
-$81.31 M
|
-$53.17 M
|
-$23.01 M
|
-$8.89 M
|
$1,000.00
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$5.94 M
|
$1.75 M
|
$62,000.00
|
-$722,000.00
|
$2,000.00
|
| Income Before Tax |
-$75.47 M |
-$51.49 M |
-$22.96 M |
-$9.61 M |
-$3.33 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$56,000.00 |
$25,000.00 |
$3,000.00 |
-$572,000.00 |
$1,000.00 |
| Net Income |
-$75.52 M |
-$51.51 M |
-$22.96 M |
-$9.04 M |
-$3.33 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
| EPS |
-2.87 |
-2.1 |
-0.94 |
-0.37 |
-0.14 |
| EPS Diluted |
-2.87 |
-2.1 |
-0.94 |
-0.37 |
-0.14 |
| Weighted Average Shares
Out |
$26.33 M
|
$24.47 M
|
$24.41 M
|
$24.41 M
|
$24.41 M
|
| Weighted Average Shares
Out Diluted |
$26.33 M
|
$24.47 M
|
$24.41 M
|
$24.41 M
|
$24.41 M
|
| Link |
|
|
|
|
|
